Calluna Pharma

Calluna Pharma appoints Margrethe Sørgaard as Senior Vice President of Clinical Operations and Pharmacovigilance

First senior executive appointment made following Company launch to oversee strategic development of clinical programmes 23 April 2024 -- Oslo, Norway -- Calluna Pharma, a clinical stage company pioneering a breakthrough approach to treating inflammatory and fibrotic diseases, today announced the appointment of Margrethe Sørgaard to the position of senior vice president (VP) of Clinical...

Calluna Pharma launches and announces €75m Series A financing to develop novel therapies for inflammatory and fibrotic diseases

Clinical stage company formed from the merger of Oxitope Pharma and Arxx Therapeutics Calluna Pharma has a pipeline of selective antibodies targeting immunological diseases New company to complete multiple clinical proofs-of-concept, across programmes Series A led by Forbion, with participation from Norwegian investors Sarsia, p53 and Investinor. 23 January 2024 -- Naarden, The Netherlands, and...
Nytt Foretak AS, Grundingen 6, 0250 Oslo, Norway.